Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

This study is offering a new CAR T-cell therapy — where immune cells are taken from a patient, genetically modified to attack cancer, and then returned to the body — to people with relapsed or treatment-resistant B-cell lymphoma using an improved manufacturing technology. **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with relapsed or refractory B-cell lymphoma (including DLBCL, mantle cell lymphoma, follicular lymphoma grades 1–3a, marginal zone lymphoma, or primary CNS DLBCL) - Your general health is reasonably good (ECOG 0–1, or ECOG 2 if caused by blood cancer) - You have adequate bone marrow function and venous access for the cell collection procedure - Your expected survival is at least 2 months **You may NOT be eligible if...** - You have other serious conditions that would make cell collection or treatment unsafe - Your cancer has not relapsed and is still responding to treatment Talk to your doctor to see if this trial is right for you.